Posted on February 15, 2019 by Sitemaster
On Thursday, here in San Francisco, Dr. Andrew Armstrong first presented the results of the so-called ARCHES trial of enzalutamide (Xtandi) + standard androgen deprivation therapy (ADT) in the treatment of men with metastatic, “hormone-sensitive” prostate cancer (mHSPC). … READ MORE …
Filed under: Uncategorized | Tagged: ADT, ARCHES, enzalutamide, hormone-sensitive, metastatic, mHSPC, Xtandi | 4 Comments »
Posted on December 20, 2018 by Sitemaster
Pfizer and Astellas have, this morning, announced that the addition of enzalutamide to standard androgen deprivation (ADT) has led to improved outcomes in men with metastatic, hormone-sensitive prostate cancer (mHSPC). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, ARCHES, deprivation, enzalutamide, hormone, outcome, sensitive, standard, trial | 2 Comments »
Posted on August 24, 2018 by Sitemaster
We note that Pfizer and Astellas have recently modified the protocols for two large, international, randomized, Phase III clinical trials to see if they can get earlier results that might affect the potential for use of enzalutamide (Xtandi) in some groups of men with hormone-sensitive prostate cancer (HSPC). … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", ARCHES, EMBARK, enzalutamide, hormone-sensitive, metastatic, trial | 6 Comments »
Posted on March 24, 2016 by Sitemaster
According to a media release issued today by Astellas Pharma and Medivation, the companies have just initiated a new, Phase III, pivotal trial of enzalutamide in men with advanced prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ARCHES, enzalutamide, hormone-sensitive, metaststic, trial | 4 Comments »